|Videos|October 12, 2017

Fosfomycin: A Novel Epoxide Antimicrobial

Evelyn J. Ellis-Grosse, PhD, chief scientific officer of Zavante Therapeutics, explains why Zavante Therapeutic’s fosfomycin is a unique, novel antimicrobial.

Evelyn J. Ellis-Grosse, PhD, chief scientific officer of Zavante Therapeutics, explains why Zavante Therapeutic’s fosfomycin is a novel antimicrobial. She also shares what the drug’s unique mechanism of action is.


Related to this article

IDSA/ESCMID Statement on Staphylococcus aureus: Follow-Up Blood Cultures
Staphylococcus aureus Bacteremia (SAB) causes significant morbidity and globally is the leading cause of death from bloodstream infection. This month, the IDSA and ESCMID released 7 consensus statements to assist in managing individuals with SAB. This review will focus on the adult patient population and additional information on pediatric population statements can be assessed in the guideline. Here is a closer look at Consensus Statement 2: Follow-up Blood Cultures.
How The Food Safety Surveillance Infrastructure Works in the US
In the first episode of our new series looking at the food safety network, Lynette Johnston, PhD, offers insights into how the federal government surveillance infrastructure operates and how epidemiologists serve as food detectives in determining bacterial pathogens and potential foodborne outbreaks.
This Week's Top 5 Infectious Disease News Stories: September 12-September 18, 2026
In this week's top infectious disease stories, a Pennsylvania teen became the state's fourth measles death in weeks, the CDC reported a 17% summer surge in rabies exposure calls, new research revisited whether cefepime raises mortality risk, a multihospital review examined ceftriaxone's safety after state alerts, and examining Legionella pneumonia diagnostics.